美股A股
StockGist
Back
10-K2026-03-04· deepseek-chat

TCRX · TScan Therapeutics, Inc.

0001193125-26-089884

SEC filing

Summary

TScan Therapeutics reported a net loss of $129.8 million for fiscal year 2025, a slight increase from a $127.5 million loss in 2024. Revenue was $10.3 million, derived entirely from collaboration and license agreements, primarily with Amgen, representing a significant increase from $2.8 million in the prior year. Operating expenses totaled $146.1 million, driven by research and development costs of $114.2 million and general and administrative expenses of $32.0 million. The company's cash position, including cash equivalents and marketable securities, was $263.8 million as of December 31, 2025. Management believes existing cash resources will fund operations into the second half of 2027. The company is prioritizing its hematologic malignancies program, including TSC-101, following a strategic restructuring that reduced the workforce by approximately 30%.

Key takeaways

Full analysis

Performance Summary

TScan Therapeutics reported a net loss of $129.8 million for the fiscal year ended December 31, 2025, compared to a net loss of $127.5 million in 2024. Revenue increased significantly to $10.3 million from $2.8 million in the prior year, driven entirely by collaboration and license revenue, primarily from the Amgen agreement. Operating expenses totaled $146.1 million, consisting of $114.2 million in research and development costs and $32.0 million in general and administrative expenses. The loss from operations was $135.8 million. Other income contributed $6.0 million, primarily from interest income. The company ended the year with $152.4 million in cash and cash equivalents and $111.4 million in marketable securities, for a total liquidity position of $263.8 million.

Revenue Analysis

Revenue for FY 2025 was $10.3 million, all derived from collaboration and license agreements. This represents a substantial increase from $2.8 million in FY 2024. The increase is primarily attributable to the timing of research activities performed under the collaboration agreement with Amgen, which commenced in May 2023. The Amgen collaboration includes an upfront payment of $30.0 million and potential success-based milestone payments of over $500 million, plus tiered royalties. The company has not generated any product revenue and does not expect to do so for several years. Future revenue is expected to depend on additional collaboration agreements, milestone achievements, and, ultimately, potential product commercialization.

Margins & Profitability

The company reported a significant operating loss of $135.8 million for FY 2025, reflecting its clinical-stage status with no commercial products. Research and development expenses of $114.2 million constituted 78.1% of total operating expenses, highlighting the company's focus on advancing its pipeline. General and administrative expenses were $32.0 million, representing 21.9% of operating costs. The company incurred $2.0 million in restructuring charges related to a workforce reduction implemented in November 2025. Non-cash stock-based compensation expense totaled $11.7 million. The net loss margin, calculated as net loss divided by revenue, was extremely high due to the minimal revenue base relative to operating expenses.

Cash Flow & Balance Sheet

Net cash used in operating activities was $135.3 million for FY 2025. Cash flows from investing activities provided $109.4 million, primarily from proceeds from maturities of marketable securities of $201.2 million, partially offset by purchases of marketable securities of $87.5 million. Cash flows from financing activities used $0.3 million. The company ended the period with total assets of $228.8 million, including current assets of $157.2 million. Total liabilities were $105.7 million, resulting in stockholders' equity of $123.1 million. Long-term debt and accrued interest stood at $32.5 million. The company's liquidity position remains strong, with management stating that existing cash and cash equivalents are expected to fund operations into the second half of 2027.

Outlook

Management has prioritized the clinical development of its hematologic malignancies program, including TSC-101 for AML and MDS, following alignment with the FDA on a registrational path. The company has paused enrollment in its solid tumor Phase 1 trial to focus preclinical efforts on in vivo engineering. A strategic restructuring in November 2025 reduced the workforce by approximately 30%, expected to produce annual cost savings of $45.0 million in 2026 and 2027. Key risks include the need for substantial additional capital to advance product candidates, reliance on third parties for clinical trials and manufacturing, intellectual property challenges, and the inherent uncertainties of drug development and regulatory approval. The company anticipates continuing significant losses for the foreseeable future.